Sign in
Not yet taking people in United StatesPhase 1

Filsuvez in Infants With Dystrophic or Junctional Epidermolysis Bullosa

Key facts

Who runs it
Medical University of South Carolina
Where
Charleston, United StatesSee the site
Trial code
Status
Not yet recruiting
Phase
Phase 1
People taking part
20 people, planned
Starts
1 Jan 2027
Expected to end
1 Jan 2029
Type of study
Interventional
Treatments tested
  • Filsuvez topical gel: 10% birch triterpenes
Record updated
16 November 2026

Who can take part

Age
0 days to 5 months
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Confirmed junctional epidermolysis bullosa or dystrophic epidermolysis bullosa diagnosis based on genetic and clinical evaluation
  • Newborns and infants aged 5 months or younger at enrollment
  • Ability of the parent or legal guardian to complete telephone assessments and comply with study procedures, as determined by the investigator
  • Written informed consent from the parent or legal guardian

Who cannot take part

  • Systemic antibiotics for a wound-related infection within 7 days before enrollment
  • Investigational therapy or systemic treatment that could interfere with wound healing within 30 days before enrollment
  • Systemic or topical steroids, except inhaled or ophthalmic steroids, within 2 weeks before enrollment
  • Enrollment in another interventional study or treatment with an investigational drug within 4 weeks before enrollment
  • Immunosuppressive therapy or cytotoxic chemotherapy within 60 days before enrollment
  • Likely need for major surgery during the study
  • Systemic infection, septicemia, or sepsis at enrollment
  • Current wound infection
  • Allergy or hypersensitivity to Filsuvez, birch triterpenes, sunflower oil, or another product component
  • Severe malnutrition or another condition that may compromise wound healing
  • Inability to follow study procedures or scheduled follow-up
  • Immediate family member of the investigational team

Where in United States

  • Medical University of South CarolinaCharleston, United StatesContact: Kennedy Louise McLeodNot yet recruiting

About the trial

What the trial wants to find out

This pilot study will evaluate the safety and tolerability of Filsuvez, a topical gel, in newborns and infants younger than 6 months with dystrophic or junctional epidermolysis bullosa. Filsuvez is approved for patients 6 months of age and older but has not been studied in this younger population. Participants will receive Filsuvez for 180 days and will be followed with clinical assessments, laboratory testing, caregiver questionnaires, telephone contacts, and standardized photographs. The study will also explore changes in wound size, disease activity, pain, and family burden during and after treatment.

The group in the trial

  • Open Label Extension of Filsuvez topical gel: 10% birch triterpenesOther group

    Filsuvez topical gel: 10% birch triterpenes will be applied with a 1mm layer to the affected wound surface and cover the wound dressing. Filsuvez should be applied directly to the dressing so that the topical gel is in direct contact with the wound. Filsuvez can be applied with standard of care bandage changes, at least every 4 days.

    Treatment: Filsuvez topical gel: 10% birch triterpenes

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot Open-Label Trial Assessing Safety of Filsuvez in Patients With Dystrophic or Junctional Epidermolysis Bullosa Under Age 6 Months
Record updated
16 November 2026